Transient response of cardiac angiosarcoma to paclitaxel.
Malignant tumours of the heart are a group of tumours with low incidence but very high mortality. Delays in diagnosis are common because of their multiple forms of presentation, and 80% present with metastases, further reducing the possibility for cure. We present here the case of a patient with primary cardiac angiosarcoma that highlights the misdiagnosis at clinical presentation, current diagnostic modalities and a possible new treatment using paclitaxel for cardiac angiosarcoma.
Castilla
E
E
Servicio de Cardiología, Hospital Clínico Universitario, Zaragoza, Spain. elena_castilla@hotmail.com
Pascual
I
I
Roncalés
F
F
Aguirre
E
E
Del Río
A
A
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017809:Fatal Outcome; D006338:Heart Neoplasms / Q000188:drug therapy*; D006394:Hemangiosarcoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000627:therapeutic use*; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel